Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yup.
I already volunteered all my information without the need for a warrant. They seemed a bit overwhelmed from the data dump. Might explain why things are taking so long.
Oh, come on now.....
... Why should facts get in the way of a narrative?
Misiu143,
If my sources are accurate, I think the mortality benefit numbers for LL in severe (CD12) looked like the following with only two 750mg injections (Day 0 and Day 7):
— 78% at 7 days
— 82% at 14 days
—50% at 21 days
—31% at 38 days
In comparison to Veru's study.....Now, if I correctly understand Sabizabulin's MOA it is very similar to colchicine.
Let's see how colchicine in randomized clinical trials faired.....
.....analysis focused on hospitalised patients only .....
....Mortality in the treatment group was 1174 (20.6%) out of 5701 and 1196 (20.6%) out of 5816 in the control group.....
There's a saying, "Sua Sponte" (Of their own accord).
This embodies how Ms. Urbach is rattling the closets for any skeletons and dealing with them - they will improvise, adapt, and overcome.
Hey...they ousted NP didn't they?
That's gotta count for something with several groups.
Can't fault Gerald Ber for cashing in a little on the upside price on Tuesday. Nice offset for the sale by the options just grante.
I think the transaction came out to about $75K and he still holds 32K shares.
I think the earnings announcement a couple of weeks ago posting around 100% over earlier estimates is really holding this up. They predict a $2.78 EPS for the current year. Not too shabby.
I wonder if there will be any mention of Vyera, Regnum, et all in the new book by Martin's former girlfriend...it's titled "Smirk"....
https://www.elle.com/culture/a39893396/christie-smythe-martin-shkreli-memoir-2022/
p.s. Good to hear the positive news on your wife.
I'm wondering if the rumor of the royalties owed LNTH (via the ProGenics acquisition) by CytoDyn might be avoided somehow. But that was during Nader Pourhassan's tenure. New leadership at CytoDyn that sound a bit more "by the books".
Wow...nice bump today with the PR announcing the clinical trial using their proprietary technetium 99m SPECT imaging agent.
This bears a much closer watching.
Crazy how it's held this price for so long. Should be an interesting ride.
BB, I hope all is improving for your wife.
Wondering if the SEC is ever going to approve Regnum's name change request. Knowing that Shkreli is still under the SEC/DOJ microscope, will Vyera, et al ever get clear of his cloud that seems to continue stalling forward progress?
Yes. Those European outlets are so easy to spot it was a dead giveaway that NP had fled the country. HAHAHA. But in reality were just the nice designer, rectangular wall outlets.
Then there was the posting of pictures of an airline ticket to Tehran that was used trying to convince people that NP had fled the US back to his birth country. Great use of factss? Hmmm....
Then there was a time where doxing of people with real and factual data was the rage...and that was a real hit....but I don't think that story has ended just yet.
Isn't this the study where Veru's placebo group had a ~42% mortality whereas all the other COVID therapeutics were in the ~25% range?
Talk about screwing with the numbers.....
Found it....
Veru's study:
Placebo group (n=52) had a 45% mortality rate compared to the sabizabulin-treated group (n=98) which had a 20% mortality rate.
We identified nine studies [9–17] with 7766 subjects, including three additional studies [13, 15, 17] following publication of the guidelines. Overall, mortality in the treatment groups was 714 (25.6%) out of 2793, and in the control groups was 1365 (27.4%) out of 4973.
Seems that the SEC finally updated the EDGAR database....
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001175680/000119312522142424/d359113d8k.htm
Good questions....and if I'm limited to these and can't offer a C), D), etc...
I'd go with B) and the reason why is that if one indication with a partnership could bounce to $3, and I'll choose LH, then a successfully funded trial paid for by the partner would greatly increase the likelihood of an EUA that would hopefully lead to a BLA. Now, granted that the partnership would need to be with a solid BP player that has deep pockets to get a trial done quickly and effectively. LH is real, it is now, and it has everyone's attention. It doesn't look like LH will be "cured" and it might require LL maintenance dosage for weeks if not months to resolve some patients issues. The recurring need will be for at least a couple of years at a fairly high number of patients - it's somewhere around 10% of COVID sufferers...and how many millions of them globally? Revenue and share price increase/stability will allow more funded trials/research that can attract more partners for other indications. Plus, having an approved drug would allow off-label use by smart physicians in ever expanding indications.
Sort of like the camel getting its nose under the edge of the tent.
Looks like the fee to renew registration is probably less than $250 USD.
https://www.sos.wa.gov/corps/feescheduleexpeditedservice.aspx
And CytoDyn has until 7/31/2022 to make their reinstatement filing and payment before things happen.
But, hey...there was a lot of arm waving, yelling, and slobbering about the same issue a couple of years ago.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155628211
And as everyone can see, CytoDyn got their reinstatement and payment in before the deadline then also.
Remember these?
[smirking]
It's been suggested that the COMMERCIALIZATION AND LICENSE AGREEMENT and the SUPPLY AGREEMENT, both dated December 17, 2019, and both between Vyera Pharmaceuticals, LLC, and CytoDyn Inc. relate to the relationship of what constitutes control of CytoDyn's IP by Regnum through these agreements.
I'm not a contractual lawyer and these are pretty lengthy documents....any help from the crowd ?
https://www.sec.gov/Archives/edgar/data/1716324/000147793222002416/rgmp_ex101.htm
https://www.sec.gov/Archives/edgar/data/1716324/000147793222002416/rgmp_ex102.htm
Anyone's guess as to what IP did CytoDyn allow RGMP access or control to?
(Quote from recent 10-K)
Third parties may in the future make claims challenging the inventorship or ownership of our intellectual property. We have written agreements with CytoDyn that provide for the ownership of intellectual property underlying the leronlimab product candidate. We may face claims by third parties that our agreements with CytoDyn are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome could have an adverse impact on our business.
Here's a tutorial from a spanish language website on how to buy your RGMP shares...
https://educacep-es.translate.goog/comprar-acciones-regnum/?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp
Does Regnum have *ANY* future/potential revenue sources other than CytoDyn?
correct, but in the world of pinky scams, institutional investors are often confused with toxic funders.
This stock is so boring and has generated nothing but losses for many investors
No wonder so many dumped it and left.
“As soon as News starts flowing” Zzzzz there is no news! None zero
Wanted to share the link for the 10-K late filing notice:
https://www.sec.gov/Archives/edgar/data/1716324/000147793222001848/rgmp_nt10k.htm
Technically it's supposed to be international. I only see some reports on other drugs from outside the US....so I guess it's up to whoever is aware of the FAERS database to submit the data.
The public data is only current up to Dec 31, 2021.
p.s. The Rem-death-is-near blew my mind on the AE's/SAE's....Death was their #3.
But where are the "safety" signals?
Certainly not in the FDA database.
Everyone is screaming "SAFETY" as a reason for the drug halt. But take a look at FDA's safety data on leronlimab.
Click here: https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/6b5a135f-f451-45be-893d-20aaee34e28e/state/analysis
Acknowledge their agreement.
Click "Search" in top left corner
Enter "leronlimab", click it to select where it moves to bottom pane, click "Go"
Now click on the top blue bar the different data sections: "Demographics", "Reaction Group", "Reaction", "Listing of Cases"
All of the safety cases reported are COVID-19 related. With death in only 1 out of 9 reports total. How many hundreds over the years have been taking for HIV, Cancer, NASH, etc ???
How the hell can the FDA say it's "safety"....wtf?!!?!/
Looks like CytoDyn's HIV BLA is going to be pushed out at least a year...I'm thinking earliest Q1 CY2023.
Treading water here....
Just a quick update. Looks like a new domain related to "Regnum Corp" has been registered. No idea if it's some sort of domain squatting effort.
https://www.regnum-corp.com/
The WhoIs entry is:
https://www.whois.com/whois/regnum-corp.com
No change to the "new" company's website at https://www.rovidatx.com ....
Of course, everything is under construction.
MM/Hedge Fund that has historically been associated with shorts (and naked shorting) targeting CYDY.....
https://franknez.com/breaking-citadel-under-investigation-by-department-of-justice/
Technically 'Citadel' is the hedge fund, and 'Citadel Securities' is a subsidiary that is a market maker.
Isn't a 10-Q supposed to be out?
Last one was for period ending 30Jun2021.
“You miss 100 percent of the shots you don't take.”
-Wayne Gretzky
But then....the holding one's breath option is still on the table...
Sure. In fact, I PROMISE. In fact, I encourage one to hold their breath until then.
If anyone doubts me, then I suggest emailing info@cytodyn.com to get their own information.
So many inquiring minds would like more information as to the validity of the "Argonaut Insurance Company" in multiple US locations. The list of their presence is fairly extensive. But I'm pretty sure inspiring minds are particularly concerned about their surety bond business - Argo Surety (https://www.argolimited.com/argo-surety/).
So, I figure I'd post that question directly on their website.
https://www.argolimited.com/contact/
I cited all the links from here that question their business validity and viability. Any email addresses for people wanting Argo Group International Holdings Ltd's response to my inquiry?
I'm pretty sure when they see who is so concerned that my inquiry will get a Priority A1 response.
Don't blink !!
Someone needs to call the US Treasury Department and inform them that an accredited company is having issues keeping some podunk website updated on Argonaut Insurance Company's status!!!!
https://www.fiscal.treasury.gov/surety-bonds/list-certified-companies.html
Nefarious "off-shore" headquarters....in Bermuda...must be the Bermuda Triangle effect....
Argo Group has quite a few locations....
https://craft.co/argo-group-international-holdings/locations
Closet.....that just slays me. Thanks for the ball-tap.
A-R-G-O-N-A-U-T I-N-S-U-R-A-N-C-E C-O-M-P-A-N-Y
For anyone trying to establish the credentials of the "Argonaut Insurance Company".....don't spell it with "Astronaut".....
https://insurance.illinois.gov/applications/RegEntPortal/ViewEntityDetails.aspx?en=82100&s=Active&t=INS
Information matches the Bond filing in the case. I'm still studying the details of the filling...but until then....check out how long Argonaut Insurance Company has been in business....not some fly-by-night or recently established shell corporation.....
I think the new management subscribes to a philosophy much different than when NP was in charge.
No half-baked PRs or CCs. No "potential" or "promising" results.
I think they'll tell us with past tense verbs that demonstrate they are action and accomplishment oriented.
I hate to say it....but I have NFI when the silence will end. I just know it is deafening.